Angiotensin-Converting Enzyme Inhibition and Renovascular Disease

Angiotensin Converting Enzyme in Sarcoidosis

Angiotensin converting enzyme inhibition and its impact on cardiovascular disease.

Ma anipulation of the renin-angiotensin system has evolved during the last few years from an obscure line of biochemical research and pathophysiologic experimentation into a new therapeutic approach, whose widespread clinical application is affecting the lives of large patient populations. Of particular interest in this respect is the emerging concept of the close relation between the renin-ang...

Nephrectomy, converting enzyme inhibition, and angiotensin peptides.

To determine the contribution of kidney-derived renin and angiotensin converting enzyme to circulating and tissue levels of angiotensin peptides, we measured angiotensin (Ang)-(1-7), Ang II, Ang-(1-9), and Ang I in plasma, kidney, lung, heart, aorta, brown adipose tissue, adrenal, pituitary, and brain of five groups of male Sprague-Dawley rats: control rats, rats given the converting enzyme inh...

Angiotensin-converting enzyme inhibition and diabetic nephropathy.

Hypertension and diabetes mellitus are strongly associated conditions from epidemiologic, genetic, and pathophysiologic points of view. The prevalence of hypertension is high in patients with diabetes, and, conversely, many patients with essential hypertension are glucose intolerant. Proteinuria appears in 40-50% of patients with insulin-dependent diabetes mellitus and 20-30% of patients with n...

Angiotensin-converting-enzyme inhibition in stable coronary artery disease.

BACKGROUND Angiotensin-converting-enzyme (ACE) inhibitors are effective in reducing the risk of heart failure, myocardial infarction, and death from cardiovascular causes in patients with left ventricular systolic dysfunction or heart failure. ACE inhibitors have also been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure. METHODS In the...